Top 10 Life Science VC (Venture Capital) Funds in Italy in October 2023

Portfolio highlights

• Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
• Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
• Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.

Portfolio highlights

• KLISBio — KLISBio is a medtech company currently developing a variety of regenerative medicine implantable products leveraging the power of silk fibroin to promote an endogenous repair of human soft tissues.
• ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
• WISE — WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

Portfolio highlights

• Easy Rain — We are Easyrain. Continuous innovation runs in our blood.With our expertise, we develop, simulate, and test solutions, launching our ideas into production. We exploit the basic laws of physics to engineer a tangible solution!
• Sibylla Biotech — Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.
• Alia Therapeutics — Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.

Portfolio highlights

• Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
• Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
• AmbAgon Therapeutics — AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.

Portfolio highlights

• Largix — Largix is the first company to develop and commercially produce 3D Robotic Printers for real production processes. We have invented the "Cold 3D Printing®" technology that makes 3DP possible for real industrial production. Largix uses the most common thermoplastic polymers: Polypropylene and Polyethylene, polymers that nobody else iscapable of printing.
• TextYess — Increase your eCommerce Retention with a Frictionless Experience.
• Electra Vehicles — Control, Analyze, & Design Innovative Battery Packs using Electra Vehicles' EVE-Ai 360 Adaptive Controls and Analytics and EnPower Design.

Portfolio highlights

• DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
• SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
• Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Portfolio highlights

• WORA — Wora is integrated with the main e-commerce platforms. For in-store purchases or via alternative channels (e.g., Instagram, WhatsApp, telephone), they make their app available to retailers to be able to send their requests easily.
• Viceversa — Viceversa provides capital to European digital businesses to support companies in sustainable and ethical growth. The company was founded in 2021 and has locations in Milan and Dublin.
• Resalis Therapeutics — Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche

Portfolio highlights

• Ecomate — The ESG Rating platform for every company
• BigProfiles — A deep understanding of customers let a company tailor marketing campaigns and CRM strategies, but companies have only basic data about customers (e.g. gender or age). External data sources like Social Networks, Public Registries and Socio-Demographic data contain rich information about billions of people, like job titles, levels of education,interests and habits.BigProfiles is a Customer Intelligence SAAS that leverages external information about persons to enrich customer profiling: it can profile a company's customers with previously unknown information about them. Thanks to its Identity Resolution algorithm (the result of a PHD), it identifies a person’s information scattered among external sources.Through this technology, BigProfiles provides customer base analytics and behavior predictions: using Artificial Intelligence on enriched profiles allows to predict churn, fraud and willingness to buy.
• Codemotion — Codemotion is the ecosystem devoted to innovation, focused on developers and coding, open to all programming languages and technologies. Pioneering spirits, it scout the future to deliver a first class experience to our people. Codemotion is one of the biggest tech-conferences in Europe, with an international network of 30.000 developers and 350speakers coming from all over the world and from the most important IT realities.Codemotion draw in its main conferences, thousands of attendees eager to discuss about hottest topics: it tailor for them disruptive proposals ranging from mobile to UX, develops, cloud, big data, gamedev, security, methods, languages, web, Internet of things. Codemotion is also a startup, providing a bunch of services and activities, for personal and business customers.

Portfolio highlights

• NeoPhore — NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
• Repron Therapeutics — Repron Therapeutics provides treatments for solid tumor cases where radical excision is not possible and metastasis or recurrence is extremely likely.
• Resalis Therapeutics — Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche

Portfolio highlights

• DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
• NMD Pharma — NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
• Bonum Therapeutics — Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.